Tanezumab for the treatment of osteoarthritis pain

Farva R. Gondal, Jawad Bilal, C. Kent Kwoh

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Tanezumab is a novel humanized IgG2 monoclonal antibody that works by selectively targeting, binding to and inhibiting nerve growth factor (NGF). NGF is upregulated in response to injury and inflammation, and preclinical data indicate it plays a role in pain signaling by inducing peripheral and central sensitization. Tanezumab potentially reduces sensitization and pain by blocking the interaction between NGF and the tropomyosin receptor kinase A (TrkA), and it has been studied extensively for the treatment of pain in patients with osteoarthritis (OA). In 2017, tanezumab was granted fast track designation in the U.S. for the treatment of chronic pain in patients with OA, as well as for the treatment of chronic low-back pain. This review discusses the mechanism of action, preclinical data and phase I, II and III studies of efficacy and safety of tanezumab in patients with OA.

Original languageEnglish (US)
Pages (from-to)187-200
Number of pages14
JournalDrugs of Today
Issue number4
StatePublished - Apr 2022


  • Analgesic drugs
  • Monoclonal antibodies
  • Nerve growth factor (NGF) inhibitors
  • Osteoarthritis pain
  • Rheumatic diseases
  • Tanezumab

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Tanezumab for the treatment of osteoarthritis pain'. Together they form a unique fingerprint.

Cite this